順豐控股(002352.SZ)擬定增募資不超220億元 40億元用於補充流動資金
格隆匯 2 月 9日丨順豐控股(002352.SZ)披露2021年度非公開發行A股股票預案,擬非公開發行股票的數量為募集資金總額除以發行價格,且不超過本次非公開發行前公司總股本的10%,即不超過455,644,045股(含455,644,045股)。
募集資金總額不超過220億元(含220億元),扣除發行費用後,60億元用於速運設備自動化升級項目,50億元用於新建湖北鄂州民用機場轉運中心工程項目,30億元用於數智化供應鏈系統解決方案建設項目,20億元用於陸路運力提升項目,20億元用於航材購置維修項目,40億元用於補充流動資金。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.